Skip to content
DataLookout
Menu

NCT03595917

ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML

StatusActive, Not Recruiting
PhasePhase 1
Primary completion (estimated)

At risk: Primary completion moved 7 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 16 versions: 14 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Nov 1, 2026 to Jun 1, 2027 Show 4 more changesShow less
    • Eligibility criteria expanded, about 59 words
    • Enrollment closed, study ongoing
    • Final enrollment: 65 participants (planned 40)
    • Site details revised at 4 of 4 sites
  2. Notable Primary completion date: Nov 1, 2025 to Nov 1, 2026
    • Study completion date: Nov 1, 2026 to Nov 1, 2027
    v15
  3. Minor Site details revised at 1 of 4 sitesv13
  4. Notable Primary completion date: Nov 1, 2023 to Nov 1, 2025
    • Study completion date: Nov 1, 2024 to Nov 1, 2026
    • Site details revised at 1 of 4 sites
    v12
  5. Minor Site details revised at 1 of 4 sitesv11
Show 8 earlier versionsHide 8 earlier versions
  1. Notable Trial status: Active, Not Recruiting to Recruitingv10 Show 6 more changesShow less
    • Eligibility criteria expanded, about 135 words
    • Enrollment target: 34 to 40
    • Interventions: ABL001 (Drug), Dasatinib (Drug), Prednisone (Drug) to ABL001 (Drug), Blinatumomab (Drug), Dasatinib (Drug), Prednisone (Drug)
    • Study description revised
    • Site details revised at 4 of 4 sites
    • Study title expanded, about 2 words
  2. Notable Lead sponsor: Marlise R. Luskin to Marlise Luskin, MD
    • Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 6 to 4
    v9
  3. Minor Study sites: 5 to 6v8
  4. Notable Primary completion date: Nov 1, 2021 to Nov 1, 2023v7
  5. Minor Study sites: 3 to 5v6
  6. Notable Primary completion date: Nov 1, 2019 to Nov 1, 2021
    • Study sites: 1 to 3
    v4
  7. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jul 2018 to Jul 24, 2018
    • Site details revised
    v3
  8. Study Identification, Study Status, Sponsor/Collaboratorsv2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Maximum tolerated dose (MTD) of ABL001
Timeframe: 42 Days

Secondary (4)

Percentage for Participants Achieving Hematologic Remission
Percentage of participants achieving cytogenetic response
Percentage of participants achieving a minimal residual disease (MRD)-negative CR by flow cytometry
Percentage of participants achieving molecular response

Arms and interventions

ABL001, Dasatinib, Prednisone, BlinatumomabExperimental

\- Dose escalation will occur conventional Fibonocci 3+3 dose escalation scheme to determine a recommended phase 2 dose (RP2D) * Dasatinib-Fixed doses oral once a day per cycle * ABL001 is administered orally daily per cycle * Prednisone-Fixed doses oral once a day per cycle. \--- Prednisone will be tapered and stop during cycle 2. * Blinatumomab - intravenous continuous infusion beginning no earlier than cycle 2 day 1 * Blinatumomab - Day 1-28 of each 42-day cycle, cycles 2-6, total of 5 cycles

Drugs: ABL001, Dasatinib, Prednisone, Blinatumomab

Sites

4 sites in 1 country